Natural killer T cells and atherosclerosis: Form and function meet pathogenesis

Journal of Innate Immunity

Volumn 2, Issue 4, 2010, Pages 316-324

  Braun, Nicole A ^a   Covarrubias, Roman ^a   Major, Amy S ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Adaptive immunity; Atherosclerosis; Chronic inflammation; Dyslipidemia; Immune regulation; Innate immunity; Natural killer T cells

Indexed keywords

LIPID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; CYTOKINE; GLYCOLIPID;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; INFECTION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; ONTOGENY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; ARTERIOSCLEROSIS; CHRONIC DISEASE; HUMAN; IMMUNOLOGY; MOUSE; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ARTERIOSCLEROSIS; CHRONIC DISEASE; CYTOKINES; DYSLIPIDEMIAS; GLYCOLIPIDS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICE; NATURAL KILLER T-CELLS;

EID: 77954079583     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000296915     Document Type: Review

References (86)

1. Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D: Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000; 20: 1417-1420. (Pubitemid 30353867)
2. Farrugia PM, Lucariello R, Coppola JT: Human immunodeficiency virus and atherosclerosis. Cardiol Rev 2009; 17: 211-215.
3. Matsuura E, Kobayashi K, Lopez LR: Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep 2009; 11: 61-69.
4. Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJ, Vogel T, Panet A, Van Berkel TJ, Kuiper J: Apolipoprotein E protects against bacterial lipopolysaccharide- induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001; 276: 8820-8824. (Pubitemid 37385453)
5. Hyka N, Dayer J-M, Modoux C, Kohno T, Edwards CK, Roux-Lombard P, Burger D: Apolipoprotein A-I inhibits the production of interleukin 1b and tumor necrosis factor-by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 2381-2389. (Pubitemid 32291485)
6. Shimaoka T, Nakayama T, Hieshima K, Kume N, Fukumoto N, Minami M, Hayashida K, Kita T, Yoshie O, Yonehara S: Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain. J Biol Chem 2004; 279: 26807-26810. (Pubitemid 38812513)
7. Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, Joyce S, Van Kaer L, Fazio S, Linton MF: Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2351-2357. (Pubitemid 39658041)
8. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Onoe K: Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104: 2051-2059. (Pubitemid 39297856)
9. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP: CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004; 199: 417-422. (Pubitemid 38252053)
10. Glass C, Witzaum J: Atherosclerosis. The road ahead. Cell 2001; 104: 503-516.
11. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.
12. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z: Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180. (Pubitemid 43214743)
13. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE: Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006; 113: 2301-2312. (Pubitemid 43947976)
14. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K: Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially Lselectin dependent. J Exp Med 2006; 203: 1273-1282. (Pubitemid 43736596)
15. de Geest B, Collen D: Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease. Eur Heart J 2001; 22: 1517-1518. (Pubitemid 32801295)
16. Wu JT, Wu LL: Autoantibodies against oxidized LDL. A potential marker for atherosclerosis. Clin Lab Med 1997; 17: 595-604. (Pubitemid 27422344)
17. Steinerova A, Racek J, Stozicky F, Zima T, Fialova L, Lapin A: Antibodies against oxidized LDL - theory and clinical use. Physiol Res 2001; 50: 131-141. (Pubitemid 32523435)
18. Paiker JE, Raal FJ, von Arb M: Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem 2000; 37: 174-178. (Pubitemid 30122241)
19. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ: Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-743. (Pubitemid 36749223)
20. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, Witztum JL: IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-437. (Pubitemid 39071615)
21. Caligiuri G, Nicoletti A, Poirier B, Hansson GK: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753. (Pubitemid 34263151)
22. Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) receptor- deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-825.
23. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W: Immunization of LDL receptordeficient mice with homologous malondialdehyde- modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-1982. (Pubitemid 28565762)
24. Wick G: Atherosclerosis - an autoimmune disease due to an immune reaction against heat-shock protein 60. Herz 2000; 25: 87-90. (Pubitemid 30238972)
25. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fisman EZ, Motro M, Shoenfeld Y: Autoantibodies to cardiolipin and beta-2-glycoprotein-I in coronary artery disease patients with and without hypertension. Cardiology 2002; 97: 2-5. (Pubitemid 34224920)
26. George J, Harats D, Shoenfeld Y: Autoimmunity in atherosclerosis. The role of autoantigens. Clin Rev Allergy Immunol 2000; 18: 73-86.
27. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-1740. (Pubitemid 30421754)
28. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800-814. (Pubitemid 26349186)
29. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573. (Pubitemid 27102148)
30. Afek A, George J, Shoenfeld Y, Gilburd B, Levy Y, Shaish A, Keren P, Janackovic Z, Goldberg I, Kopolovic J, Harats D: Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 1999; 67: 19-25. (Pubitemid 29037607)
31. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y: Induction of early atherosclerosis in LDLreceptor- deficient mice immunized with 2 - glycoprotein I. Circulation 1998; 98: 1108-1115.
32. Afek A, George J, Gilburd B, Rauova L, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y: Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 2000; 14: 115-121. (Pubitemid 30662571)
33. Major AS, Fazio S, Linton MF: B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002; 22: 1892-1898. (Pubitemid 35315778)
34. Andersson J, Libby P, Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol 2010; 134: 33-46.
35. Packard RR, Lichtman AH, Libby P: Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009; 31: 5-22.
36. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, Witztum JL: The role of innate immunity in atherogenesis. J Lipid Res 2009; 50(suppl):S388-S393.
37. Tabas I: Apoptosis and efferocytosis in mouse models of atherosclerosis. Curr Drug Targets 2007; 8: 1288-1296.
38. Doherty TM, Fisher EA, Arditi M: TLR signaling and trapped vascular dendritic cells in the development of atherosclerosis. Trends Immunol 2006; 27: 222-227.
39. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M: Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009; 120: 2462-2469.
40. Lee JG, Lim EJ, Park DW, Lee SH, Kim JR, Baek SH: A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal 2008; 20: 2266-2275.
41. Bendelac A, Rivera MN, Park SH, Roark JH: Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535-562. (Pubitemid 27169416)
42. Kronenberg M, Gapin L: The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002; 2: 557-568. (Pubitemid 37328731)
43. Gigli G, Caielli S, Cutuli D, Falcone M: Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 2007; 122: 409-417. (Pubitemid 47556478)
44. Nowak M, Stein-Streilein J: Invariant NKT cells and tolerance. Int Rev Immunol 2007; 26: 95-119. (Pubitemid 46512167)
45. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1801-1811. (Pubitemid 34028659)
46. Wang B, Geng YB, Wang CR: CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194: 313-320. (Pubitemid 32730805)
47. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, Takabayashi K, Takahashi H, Yoshida S, Taniguchi M, Saito Y, Iwamoto I: Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 275-283. (Pubitemid 32165132)
48. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E, Fukushima H: Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995; 38: 2176-2187.
49. Tupin E, Kinjo Y, Kronenberg M: The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007; 5: 405-417. (Pubitemid 46780078)
50. Wilson MT, Singh AK, Van Kaer L: Immunotherapy with ligands of natural killer T cells. Trends Mol Med 2002; 8: 225-231. (Pubitemid 34493640)
51. Yang Y, Bao M, Yoon JW: Intrinsic defects in the T-cell lineage results in natural killer Tcell deficiency and the development of diabetes in the nonobese diabetic mouse. Diabetes 2001; 50: 2691-2699. (Pubitemid 33733119)
52. Wu D, Xing GW, Poles MA, Horowitz A, Kinjo Y, Sullivan B, Bodmer-Narkevitch V, Plettenburg O, Kronenberg M, Tsuji M, Ho DD, Wong CH: Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005; 102: 1351-1356. (Pubitemid 40209173)
53. Godfrey DI, Berzins SP: Control points in NKT-cell development. Nat Rev Immunol 2007; 7: 505-518.
54. Gapin L, Matsuda JL, Surh CD, Kronenberg M: NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2001; 2: 971-978. (Pubitemid 32976171)
55. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A: A thymic precursor to the NK T cell lineage. Science 2002; 296: 553-555. (Pubitemid 34408679)
56. Pellicci DG, Hammond KJ, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI: A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1(-) CD4(+) CD1d-dependent precursor stage. J Exp Med 2002; 195: 835-844.
57. McNab FW, Pellicci DG, Field K, Besra G, Smyth MJ, Godfrey DI, Berzins SP: Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts. J Immunol 2007; 179: 6630-6637.
58. Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL, Kronenberg M: Mouse CD1 is mainly expressed on hemopoietic- derived cells. J Immunol 1997; 159: 1216-1224. (Pubitemid 127484098)
59. Kang SJ, Cresswell P: Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat Immunol 2004; 5: 175-181. (Pubitemid 38208359)
60. Zhou D, Cantu C 3rd, Sagiv Y, Schrantz N, Kulkarni AB, Qi X, Mahuran DJ, Morales CR, Grabowski GA, Benlagha K, Savage P, Bendelac A, Teyton L: Editing of CD1dbound lipid antigens by endosomal lipid transfer proteins. Science 2004; 303: 523-527. (Pubitemid 38120850)
61. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA: Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997; 277: 339-345. (Pubitemid 27450700)
62. Van Kaer L: NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 2007; 19: 354-364. (Pubitemid 46687006)
63. Brigl M, Brenner MB: How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol 2009, E-pub ahead of print.
64. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, Zajonc DM, Ben-Menachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Beutler B, Wilson IA, Tsuji M, Sellati TJ, Wong CH, Kronenberg M: Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006; 7: 978-986. (Pubitemid 44263912)
65. Olson CM Jr, Bates TC, Izadi H, Radolf JD, Huber SA, Boyson JE, Anguita J: Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. J Immunol 2009; 182: 3728-3734.
66. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR: Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005; 35: 1692-1701. (Pubitemid 40862317)
67. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M: CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629. (Pubitemid 27516282)
68. Wilson MT, Singh AK, Van Kaer L: Immunotherapy with ligands of natural killer T cells. Trends Mol Med 2002; 8: 225-231. (Pubitemid 34493640)
69. Brutkiewicz RR, Sriram V: Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002; 41: 287-298. (Pubitemid 34203665)
70. Brutkiewicz RR: CD1d ligands: the good, the bad, and the ugly. J Immunol 2006; 177: 769-775.
71. Crowe NY, Smyth MJ, Godfrey DI: A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002; 196: 119-127. (Pubitemid 34747317)
72. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C: An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007; 110: 2013-2019. (Pubitemid 47443916)
73. Godfrey DI, Kronenberg M: Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379-1388. (Pubitemid 40385565)
74. Miyamoto K, Miyake S, Yamamura T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-534. (Pubitemid 32938752)
75. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DA: Extreme Th1 bias of invariant V 24J Q T cells in type 1 diabetes. Nature 1998; 391: 177-181. (Pubitemid 28092476)
76. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF: Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26: 2989-2998. (Pubitemid 26411504)
77. Bobryshev YV, Lord RS: Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J Histochem Cytochem 2005; 53: 781-785.
78. Chan WL, Pejnovic N, Hamilton H, Liew TV, Popadic D, Poggi A, Khan SM: Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ Res 2005; 96: 675-683. (Pubitemid 40478335)
79. VanderLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, Nissenbaum M, Wang CR, Getz GS: Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol 2007; 170: 1100-1107. (Pubitemid 47339376)
80. Rogers L, Burchat S, Gage J, Hasu M, Thabet M, Willcox L, Ramsamy TA, Whitman SC: Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. Cardiovasc Res 2008; 78: 167-174. (Pubitemid 351430959)
81. Aslanian AM, Chapman HA, Charo IF: Transient role for CD1d-restricted natural killer T Cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005; 25: 628-632.
82. To K, Agrotis A, Besra G, Bobik A, Toh BH: NKT cell subsets mediate differential proatherogenic effects in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2009; 29: 671-677.
83. van Puijvelde GH, van Wanrooij EJ, Hauer AD, de Vos P, van Berkel TJ, Kuiper J: Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb Haemost 2009; 102: 223-230.
84. van den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, Brenner MB: Apolipoprotein- mediated pathways of lipid antigen presentation. Nature 2005; 437: 906-910. (Pubitemid 41486768)
85. Allan LL, Hoefl K, Zheng DJ, Chung BK, Kozak FK, Tan R, van den Elzen P: Apolipoprotein- mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood 2009; 114: 2411-2416.
86. Miyazaki Y, Iwabuchi K, Iwata D, Miyazaki A, Kon Y, Niino M, Kikuchi S, Yanagawa Y, Kaer LV, Sasaki H, Onoe K: Effect of high fat diet on NKT cell function and NKT cell-mediated regulation of Th1 responses. Scand J Immunol 2008; 67: 230-237. (Pubitemid 351197163)